AU Patent

AU2019200160B2 — Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one

Assigned to Gilead Calistoga LLC · Expires 2020-01-16 · 6y expired

What this patent protects

Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin 4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.

USPTO Abstract

Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin 4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number: AU2019200160B2
Jurisdiction: AU
Classification: —
Expires: 2020-01-16
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Calistoga LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.